AUTL · Health care(biological products, (no diagnostic substances)) · 10 years of annual accounts filed with the SEC · latest fiscal year ended 2025-12-31
Signed in, this page also says what this company is inside your own portfolio: its weight, its share of your risk, and what buying or selling some of it would change. Sign in ›
Autolus Therapeutics plc reported revenue of $75.4 million in fiscal 2025. On the accounting screens, it passes 2 of 8 Piotroski tests, its Altman Z'' of -6.27 is in the distress zone and its Beneish M-score is above the -1.78 line; 4 of the six cross-checks between its statements fire.
Revenue, fiscal 202575.4M
Operating margin-358.9%gross margin -27.8%
Return on invested capital—
Free cash flow after stock pay-317.0M-420.6% of revenue
Net debt ÷ EBITDA—net debt —
Piotroski F-score2/8tests of improvement passed
Share counts are in today's shares. The SEC's filings restate only recent years after a split, so these jumps were read as splits and the older years scaled to match — otherwise per-share figures would compare different units:
2-for-1 before fiscal 2023.
Is it growing?
Revenue and the operating income it turns into. Growth that does not reach operating income is growth bought with margin.
RevenueOperating income
-300M-200M-100M0100M
2022
2022
2022
2022Operating income -143.4M
2023
2023
2023
2023Revenue 1.7MOperating income -179.7M
2024Revenue 10.1MOperating income -241.4M
2025Revenue 75.4MOperating income -270.5M
2022202220222022202320232023202320242025
Does it earn more than its capital costs?
Margins say how much of each sale is kept; return on invested capital says how much the business earns on the money it needs to operate. Growth only creates value when that return is above the cost of the capital.
Needs a cost of capital, which comes from the valuation below.
Return on equity
-161.4%
Return on assets
-48.8%
Asset turnover
0.13×
Research & development
156.1% of revenue
Overheads (SG&A)
174.9% of revenue
Is the profit cash, and where does the cash go?
Net income is an accounting opinion; free cash flow is what was left in the bank after investing. Stock-based pay does not leave the bank — shareholders pay it through dilution — so it is shown taken off as well.
Net incomeFree cash flowAfter stock-based pay
-400M-300M-200M-100M0
2022
2022
2022
2022Net income -148.8MFree cash flow -123.1MAfter stock-based pay -135.2M
2023
2023
2023
2023Net income -208.4MFree cash flow -156.6MAfter stock-based pay -167.8M
2024Net income -220.7MFree cash flow -228.3MAfter stock-based pay -243.8M
2025Net income -287.5MFree cash flow -302.6MAfter stock-based pay -317.0M
2022202220222022202320232023202320242025
Per share
Earnings per shareFree cash flow per shareDividend per share
-$1.50-$1.00-$0.50$0.00
2022
2022
2022
2022Earnings per share $-0.78Free cash flow per share $-0.65
2023
2023
2023
2023Earnings per share $-1.20Free cash flow per share $-0.90
2024Earnings per share $-0.86Free cash flow per share $-0.89
2025Earnings per share $-1.08Free cash flow per share $-1.14
2022202220222022202320232023202320242025
Shares outstanding
Diluted shares
150M175M200M225M250M275M
2022
2022
2022
2022Diluted shares 190.0M
2023
2023
2023
2023Diluted shares 173.9M
2024Diluted shares 255.2M
2025Diluted shares 266.1M
2022202220222022202320232023202320242025
Debt and liquidity
Debt is not bad in itself; debt the business cannot service in a bad year is. Net debt is debt minus cash, and below zero the company holds more cash than it owes.
Net debt ÷ EBITDA
—
Interest coverage
-7× operating income ÷ interest
Current ratio
5.94 current assets ÷ current liabilities
Cash conversion cycle
230 days collects in 116d, stock 126d, pays in 12d
Three classic screens of the accounts
Each asks a different question of the same statements — is it improving, does it look like a company heading for distress, do the accounts resemble ones that were manipulated. None is a verdict; each shows what moves it.
Piotroski F-score
Is the business improving? Nine yes-or-no tests, this year against last.
2of 8 tests passed
✕ProfitableReturn on assets above zerofailed
✕Cash from operationsOperating cash flow above zerofailed
✕Profitability improvedReturn on assets higher than a year beforefailed
✓Profit backed by cashOperating cash flow above net income (low accruals)passed
–Less long-term debtLong-term debt as a share of assets fell — not reportedno data
✕More liquidCurrent ratio higher than a year beforefailed
✕No new sharesShare count did not growfailed
✕Better gross marginGross margin higher than a year beforefailed
✓Sells more per assetAsset turnover higher than a year beforepassed
Where it misleads: it measures change, not level. An excellent business that stood still for a year scores low; a poor one recovering from a disaster scores high.
Altman Z''-score
Does the balance sheet look like those of companies that went bankrupt?
-6.27distress zone
1.12.6
Working capital ÷ assets 0.62 × 6.56+4.04
Retained earnings ÷ assets -2.35 × 3.26-7.67
Operating income ÷ assets -0.46 × 6.72-3.09
Equity ÷ liabilities 0.43 × 1.05+0.46
Where it misleads: buybacks. A company that returns so much cash that its equity turns small or negative sinks the last two ratios without being anywhere near bankruptcy. Banks and insurers do not fit the model at all.
Beneish M-score
Do the accounts resemble those of companies that manipulated their earnings?
200.05above the -1.78 line
-1.78
Receivables vs sales 215.00+197.80
Gross margin slipping 0.45+0.24
Soft assets 1.65+0.67
Sales growth 7.45+6.64
Slower depreciation 1.15+0.13
Overheads vs sales 0.17-0.03
Profit not in cash -0.01-0.03
Leverage rising 1.61-0.53
Where it misleads: fast growth and acquisitions. Sales growth carries a heavy weight, so a company growing 50% a year scores like a suspect without having done anything. It is a screen from a 1999 study, not an accusation.
Where the statements disagree
Cross-checks between the income statement, the balance sheet and the cash flow for the latest year, each with the benign reading and the worrying one.
Receivables are growing 160060% against revenue growing 645%.
Benign
A shift towards larger customers on longer terms, or sales concentrated at the end of the period.
Worrying
Sales are being made on looser credit, or revenue has been booked that may never be collected.
Inventory is growing 703% against revenue growing 645%.
Benign
Stocking up for a launch, or securing supply.
Worrying
Demand is softening; discounts or write-downs tend to follow.
Reported profit comfortably exceeds the cash generated (-288M against -284M).
Benign
Growth consuming working capital, or the seasonality of the year-end.
Worrying
Profit held up by accounting entries that do not turn into money.
The effective tax rate is -0.7%.
Benign
A favourable geographic mix, or legitimate tax credits.
Worrying
Not sustainable; projecting it forward inflates the valuation.
What is it worth, under which assumptions?
A company is worth the cash it will generate, brought back to today. This model projects revenue with growth that fades over the years, applies a free cash flow margin, and discounts the result at the cost of capital. Every assumption says where it came from, and all of them can be changed.
With a free cash flow margin at or below zero in year ten, the business never generates cash for its owners and a DCF says nothing useful. Set a positive margin for year ten to see what it would take.
What it has filed lately
The last twelve months at the SEC, most important first: annual and quarterly reports, events, large holders and insiders.
Every Form 4 filed in the last twelve months, read line by line: 6 filings by 6 people. Open-market purchases and sales are counted apart from awards, option exercises and shares withheld for taxes.
Bought on the open market—none in the period
Sold on the open market$15,6821 sale(s) by 1 insider(s)
Under pre-arranged plans0%of the sales followed a 10b5-1 plan set months earlier
A Form 4 says what happened, when, how many shares and at what price. It does not say why: a sale can be diversification, a tax bill or a plan fixed months earlier, and an award is pay, not a purchase. Nothing here is a reason to buy or sell anything.
Companies like this one
Same SEC industry (biological products, (no diagnostic substances)) first, then the rest of health care.
Accounts from the company's own SEC filings; lines some companies do not report are shown as a dash rather than estimated. The risk-free rate is the 10-year US Treasury yield. A DCF is a way of making assumptions explicit, not a forecast: it states what the company would be worth if the assumptions held. The scores are screens that point where to look, not verdicts. Nothing here is a recommendation to buy or sell.
